The new study would change how medicine was practiced, cancer specialists said.

These drugs will attack cancer cells in the body without damaging surrounding healthy ones.

Britain's second-biggest drugmaker has rejected a $106 billion approach from its US rival Pfizer, arguing that it has a bright future.